Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Becton Dickinson and Company

The latest update is out from GSH ( ($SG:BDX) ). GSH Corporation has disclosed a renewed arbitration move against its subsidiary Investasia Sdn. Bh...

GSH Faces Renewed RM143.2 Million Arbitration Claim Against Subsidiary

In a report released on July 6, Joanne Wuensch from Citi reiterated a Buy rating on Becton Dickinson, with a price target of $198.00. The company’s...

Citi Reaffirms Their Buy Rating on Becton Dickinson (BDX)

BCAL Diagnostics Limited ( ($AU:BDX) ) just unveiled an update. BCAL Diagnostics has acquired a 10.2% stake, or 23,173,644 shares, in molecular dia...

BCAL buys 10.2% stake in Genetic Signatures to broaden diagnostics platform

An announcement from BCAL Diagnostics Limited ( ($AU:BDX) ) is now available. BCAL Diagnostics has strengthened its funding position for fiscal 202...

BCAL Diagnostics secures funding to drive cancer test commercialisation through FY2027

BCAL Diagnostics Limited ( ($AU:BDX) ) just unveiled an update. BCAL Diagnostics has unveiled BREASTEST Monitor, a new blood test designed to evalu...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BDX	$151.94	+0.72%	1.03M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BDX	$151.94	+0.7%	1.03M
3
4
5
6

BDX

BDX

Get Becton Dickinson and Company Data in Excel

Get Becton Dickinson and Company Data in Excel